Skip to main content
Premium Trial:

Request an Annual Quote

Bayer Will Use Stratagene s QPCR Platform to Develop Instrument for IVD Market

NEW YORK, March 14 (GenomeWeb News) - Stratagene said today that Bayer Healthcare's diagnostics division will purchase minimally customized versions of Stratagene's Mx3005P QPCR instrument for use in a new platform Bayer is developing for molecular diagnostic tests.

 

As reported last week in BioCommerce Week, a GenomeWeb News sister publication, Stratagene will develop customized software and system features for the Mx3005P instrument for Bayer, and will receive milestone payments based upon its completion of this customization and regulatory activities needed to meet Bayer's clinical requirements.

 

Bayer will use the instruments as components in its modular quantitative PCR systems, which will expand Bayer's product portfolio in the in vitro diagnostic market, the companies said.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.